ESR1 and breast cancer: However, in MCF-7 cells, which are ERα and PR positive, vorinostat can deplete ERα at both transcriptional and post-translational for protein levels by inhibiting ERα gene expression and stimulating ubiquitin–proteasome pathway degradation, which could serve as a novel therapy for hormone-refractory BC [45].